Disease · MONDO_0001325
penile cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. penile cancer. Diseases, record MONDO_0001325. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001325
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of penis, malignant neoplasm of penis, malignant neoplasm of the penis, malignant penile neoplasm, malignant penile tumor, malignant penile tumour, malignant penis neoplasm, malignant tumor of penis, malignant tumor of the penis, malignant tumour of penis, malignant tumour of the penis, penis cancer
- Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| IFOSFAMIDE | CHEMBL1024 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BINTRAFUSP ALFA | CHEMBL4298024 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TORIPALIMAB | CHEMBL4297843 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets31
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 1 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
1 to 10 of 31
See all 31 targetsTrials22
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | Phase 1/2 | 578 | 2022-04-12 | Various Advanced Cancer | DARATUMUMAB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Phase 1/2 | 224 | 2026-03-09 | Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | Phase 2 | 57 | 2022-02-28 | Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer | BINTRAFUSP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Phase 1/2 | 51 | 2023-11-18 | Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, PEXIPEPIMUT-S | Its record names the disease | ClinicalTrials.gov |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | Phase 2 | 29 | 2017-03-23 | Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | Phase 1/2 | 12 | 2017-08-02 | Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | Phase 2 | 400 | Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors | IVONESCIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | Phase 2 | 269 | Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability, Penile Neoplasms, Cancer With POLE Exonucleasic Domain Mutation | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | 200 | Squamous Cell Carcinoma of the Penis, Usual Type | CISPLATIN, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | Phase 2 | 100 | Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer, Urachal Cancer | CISPLATIN, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: serious adverse events | 18 of 47 | 1 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cervical vs NonCervical: Number of Patients With Serious and Non-serious Adverse Events | 18 of 18 | 11 of 11 | 29 | NCT01585428 | Trial comparisons |
| Cervical vs NonCervical: deaths from any cause | 1 of 18 | 0 of 11 | 29 | NCT01585428 | Trial comparisons |
| Cervical vs NonCervical: serious adverse events | 4 of 18 | 2 of 11 | 29 | NCT01585428 | Trial comparisons |
Papers from its trials15
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 33558725 | RESULT | 1 | PubMed |
| 25823737 | RESULT | 1 | PubMed |
| 41445185 | DERIVED | 1 | PubMed |
| 40116923 | DERIVED | 1 | PubMed |
| 39976981 | DERIVED | 1 | PubMed |
| 39889250 | DERIVED | 1 | PubMed |
| 38608691 | DERIVED | 1 | PubMed |
| 38340723 | DERIVED | 1 | PubMed |
| 37487169 | DERIVED | 1 | PubMed |
| 34083421 | DERIVED | 1 | PubMed |
1 to 10 of 15
See all 15 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001325
GET https://conductscience.org/api/diseases/v1/MONDO_0001325/drugs?page=2